APA (7th ed.) Citation

C, H., J, B., JS, H., Y, M., A, N., M, D., . . . JS, W. (2024). FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion. Frontiers in oncology, 14, 1367450. https://doi.org/10.3389/fonc.2024.1367450

Chicago Style (17th ed.) Citation

C, Hackenbruch, et al. "FusionVAC22_01: A Phase I Clinical Trial Evaluating a DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition for Fibrolamellar Hepatocellular Carcinoma and Other Tumor Entities Carrying the Oncogenic Driver Fusion." Frontiers in Oncology 14 (2024): 1367450. https://doi.org/10.3389/fonc.2024.1367450.

MLA (9th ed.) Citation

C, Hackenbruch, et al. "FusionVAC22_01: A Phase I Clinical Trial Evaluating a DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition for Fibrolamellar Hepatocellular Carcinoma and Other Tumor Entities Carrying the Oncogenic Driver Fusion." Frontiers in Oncology, vol. 14, 2024, p. 1367450, https://doi.org/10.3389/fonc.2024.1367450.